Active Filter(s):
Details:
ATI-2042 (budiodarone) is a potentially best-in-class mixed ion channel blocker. It is being evaluated for the treatment of symptomatic non-permanent atrial fibrillation.
Lead Product(s): Budiodarone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ATI-2042
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024